NASDAQ:FHTX Foghorn Therapeutics (FHTX) Stock Price, News & Analysis $2.05 +0.05 (+2.50%) Closing price 04:00 PM EasternExtended Trading$2.00 -0.05 (-2.68%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Foghorn Therapeutics Stock (NASDAQ:FHTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Foghorn Therapeutics alerts:Sign Up Key Stats Today's Range$1.93▼$2.0650-Day Range$1.85▼$7.0752-Week Range$1.79▼$7.61Volume509,734 shsAverage Volume1.41 million shsMarket Capitalization$121.73 millionP/E RatioN/ADividend YieldN/APrice Target$6.14Consensus RatingHold Company Overview Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing medicines that target the chromatin regulatory system, which controls how DNA is packaged and how genes are expressed. The company’s research is directed primarily toward cancer therapies, particularly for tumors driven by abnormalities in chromatin-remodeling proteins. Foghorn uses its proprietary Gene Traffic Control platform to identify and develop small-molecule treatments designed to modulate chromatin-regulating complexes. Its pipeline has included FHD-609, a BRD9-targeting protein degrader, and FHD-286, an inhibitor intended to address vulnerabilities associated with the BRG1 and BRM chromatin-remodeling proteins. These programs have been evaluated in selected hematologic and solid-tumor indications. Founded in 2015 and headquartered in Cambridge, Massachusetts, Foghorn conducts drug discovery and clinical development activities for patients in the United States and other regions where its studies are authorized. The company has also pursued research collaborations with larger pharmaceutical companies to advance programs based on its chromatin biology platform. Adrian Gottschalk serves as Foghorn Therapeutics’ president and chief executive officer.AI Generated. May Contain Errors. Read More Foghorn Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreFHTX MarketRank™: 3.02336204646 of 5 starsFoghorn Therapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 482nd out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingFoghorn Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on no strong buy ratings, 4 buy ratings, 6 hold ratings, and 1 sell rating.Upside PotentialFoghorn Therapeutics has a consensus price target of $6.14, representing about 199.7% upside from its current price of $2.05.Amount of Analyst CoverageFoghorn Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Foghorn Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Foghorn Therapeutics are expected to decrease in the coming year, from ($0.86) to ($0.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Foghorn Therapeutics is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Foghorn Therapeutics is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Foghorn Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.54% of the float of Foghorn Therapeutics has been sold short.Short Interest Ratio / Days to CoverFoghorn Therapeutics has a short interest ratio ("days to cover") of 1.17, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Foghorn Therapeutics has recently increased by 14.05%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldFoghorn Therapeutics does not currently pay a dividend.Dividend GrowthFoghorn Therapeutics does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.55 News SentimentFoghorn Therapeutics has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Foghorn Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for FHTX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows1 people have added Foghorn Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Foghorn Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders9.02% of the stock of Foghorn Therapeutics is held by insiders.Percentage Held by Institutions61.55% of the stock of Foghorn Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Foghorn Therapeutics' insider trading history. Receive FHTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Foghorn Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FHTX Stock News HeadlinesFoghorn Therapeutics consensus price target decreased by 44.38% to $5.61October 22, 2026 | msn.comFoghorn Therapeutics (FHTX) Stock Fair Value Moves Lower After Pipeline And Lilly ResetOctober 22, 2026 | finance.yahoo.comMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community before the big move happened. Now, I'm making my next big call. It's a coin under $1.00 that most investors have never heard of. But the world's largest bank is already building on it. It has a deflationary burn mechanism tied directly to institutional usage. With Bitcoin well off its highs and fear still hanging over the market, this is the exact environment where my biggest winners have been found.October 26 at 1:00 AM | Crypto 101 Media (Ad)INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTXOctober 22, 2026 | prnewswire.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Stock Has Average Target Price of $6.14October 22, 2026 | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTXOctober 20, 2026 | globenewswire.comFoghorn Therapeutics (NASDAQ:FHTX) Cut to "Hold" at EvercoreOctober 16, 2026 | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTXOctober 15, 2026 | prnewswire.comSee More Headlines FHTX Stock Analysis - Frequently Asked Questions How have FHTX shares performed this year? Foghorn Therapeutics' stock was trading at $5.40 at the beginning of the year. Since then, FHTX shares have decreased by 62.0% and is now trading at $2.05. How were Foghorn Therapeutics' earnings last quarter? Foghorn Therapeutics Inc. (NASDAQ:FHTX) announced its earnings results on Thursday, August, 6th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.15. The company had revenue of $16.07 million for the quarter, compared to the consensus estimate of $6.81 million. When did Foghorn Therapeutics IPO? Foghorn Therapeutics (FHTX) raised $120 million in an IPO on Friday, October 23rd 2020. The company issued 7,500,000 shares at $15.00-$17.00 per share. Goldman Sachs, Morgan Stanley and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. How do I buy shares of Foghorn Therapeutics? Shares of FHTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Foghorn Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Foghorn Therapeutics investors own include Bicycle Therapeutics (BCYC), Nkarta (NKTX), Vir Biotechnology (VIR), Verastem (VSTM), Acrivon Therapeutics (ACRV), Aligos Therapeutics (ALGS) and Allogene Therapeutics (ALLO). Company Calendar Last Earnings8/06/2026Today10/26/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 3 weeks, FHTX's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:FHTX CIK1822462 Webfoghorntx.com Phone617-586-3100FaxN/AEmployees106Year Founded2016Price Target and Rating Average Price Target for Foghorn Therapeutics$6.14 High Price Target$12.00 Low Price Target$2.00 Potential Upside/Downside+199.7%Consensus RatingHold Rating Score (0-4)2.27 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($0.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$74.28 million Net Margins-175.78% Pretax Margin-175.78% Return on EquityN/A Return on Assets-31.17% Debt Debt-to-Equity RatioN/A Current Ratio3.36 Quick Ratio3.36 Sales & Book Value Annual Sales$30.91 million Price / Sales3.94 Cash FlowN/A Price / Cash FlowN/A Book Value($1.92) per share Price / Book-1.07Miscellaneous Outstanding Shares59,380,000Free Float54,028,000Market Cap$121.73 million OptionableOptionable Beta3.01 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:FHTX) was last updated on 10/26/2026 by MarketBeat.com Staff. From Our PartnersTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredMy Deep Cut Pick Before Anthropic's IPOThe biggest IPO in history is likely just weeks away... at a valuation of up to $2 trillion Anthropic could ma...Crypto 101 Media | SponsoredMissed this in 2024? Here’s your second chanceIn April 2024, gold had gone nowhere for 13 years - then it surged to a record high, more than doubling in val...Traders Agency | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Foghorn Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Foghorn Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
